View ValuationLavipharm 将来の成長Future 基準チェック /06現在、 Lavipharmの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長23.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 21Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Board Member Vasiliki Kefalas was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026お知らせ • Mar 15Lavipharm S.A., Annual General Meeting, Jul 03, 2025Lavipharm S.A., Annual General Meeting, Jul 03, 2025.お知らせ • Nov 01Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024Reported Earnings • Sep 21Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023).お知らせ • Sep 02Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024Valuation Update With 7 Day Price Move • Jul 13Investor sentiment improves as stock rises 31%After last week's 31% share price gain to €1.02, the stock trades at a trailing P/E ratio of 71.9x. Average trailing P/E is 29x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 51% over the past year.Reported Earnings • May 29First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: €0.005. Revenue: €13.2m (down 4.6% from 1Q 2023). Net income: €780.0k (up 32% from 1Q 2023). Profit margin: 5.9% (up from 4.3% in 1Q 2023).お知らせ • May 01Lavipharm S.A. to Report Q1, 2024 Results on May 23, 2024Lavipharm S.A. announced that they will report Q1, 2024 results at 5:20 PM, GTB Standard Time on May 23, 2024New Risk • Apr 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €50.9m (up 11% from FY 2022). Net income: €2.00m (up 139% from FY 2022). Profit margin: 3.9% (up from 1.8% in FY 2022). The increase in margin was driven by higher revenue.お知らせ • Mar 01Lavipharm S.A. to Report Fiscal Year 2023 Results on Mar 21, 2024Lavipharm S.A. announced that they will report fiscal year 2023 results on Mar 21, 2024New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin).New Risk • Nov 10New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.5% Last year net profit margin: 2.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Minor Risk Profit margins are more than 30% lower than last year (0.5% net profit margin).お知らせ • Nov 01Lavipharm S.A. to Report Nine Months, 2023 Results on Nov 08, 2023Lavipharm S.A. announced that they will report nine months, 2023 results on Nov 08, 2023Board Change • Oct 19Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Board Member Vicky Kefalas was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 24Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €15.6m (up 52% from 2Q 2022). Net income: €1.63m (up 63% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022).Board Change • Sep 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Board Member Vicky Kefalas was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 01Lavipharm S.A. to Report First Half, 2024 Results on Sep 21, 2023Lavipharm S.A. announced that they will report first half, 2024 results on Sep 21, 2023Board Change • May 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Mar 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 17First half 2022 earnings released: EPS: €0.037 (vs €0.15 in 1H 2021)First half 2022 results: EPS: €0.037 (down from €0.15 in 1H 2021). Revenue: €21.2m (up 8.4% from 1H 2021). Net income: €1.90m (down 27% from 1H 2021). Profit margin: 9.0% (down from 13% in 1H 2021). The decrease in margin was driven by higher expenses.Board Change • Aug 31Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Lavipharm は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:BXA0 - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202563527N/A9/30/2025552N/AN/AN/A6/30/2025552-61N/A3/31/2025539N/AN/AN/A12/31/2024539-54N/A9/30/2024469N/AN/AN/A6/30/2024478-42N/A3/31/2024522N/AN/AN/A12/31/2023482-40N/A9/30/2023540N/AN/AN/A6/30/2023441-342N/A3/31/2023491N/AN/AN/A12/31/2022391-323N/A9/30/2022432N/AN/AN/A6/30/202241135N/A3/31/2022411N/AN/AN/A12/31/202140224N/A9/30/202139223N/A6/30/202139313N/A3/31/202138213N/A12/31/202038213N/A9/30/202037413N/A6/30/202036714N/A3/31/202035613N/A12/31/201934503N/A9/30/2019343N/A2N/A6/30/2019341N/A1N/A3/31/2019341N/A1N/A12/31/2018341N/A1N/A9/30/2018330N/A2N/A6/30/201832-1N/A2N/A3/31/2018326N/A2N/A12/31/20173213N/A2N/A9/30/20173211N/A1N/A6/30/20173210N/A1N/A3/31/2017327N/A1N/A12/31/2016314N/A1N/A9/30/2016314N/A1N/A6/30/2016284N/A1N/A3/31/201627-2N/A0N/A12/31/201526-7N/A1N/A9/30/201527-9N/A1N/A6/30/201529-9N/A2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BXA0の予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BXA0の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BXA0の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BXA0の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BXA0の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BXA0の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 22:10終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Lavipharm S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 21Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Board Member Vasiliki Kefalas was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026
お知らせ • Mar 15Lavipharm S.A., Annual General Meeting, Jul 03, 2025Lavipharm S.A., Annual General Meeting, Jul 03, 2025.
お知らせ • Nov 01Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024
Reported Earnings • Sep 21Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023).
お知らせ • Sep 02Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024
Valuation Update With 7 Day Price Move • Jul 13Investor sentiment improves as stock rises 31%After last week's 31% share price gain to €1.02, the stock trades at a trailing P/E ratio of 71.9x. Average trailing P/E is 29x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 51% over the past year.
Reported Earnings • May 29First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: €0.005. Revenue: €13.2m (down 4.6% from 1Q 2023). Net income: €780.0k (up 32% from 1Q 2023). Profit margin: 5.9% (up from 4.3% in 1Q 2023).
お知らせ • May 01Lavipharm S.A. to Report Q1, 2024 Results on May 23, 2024Lavipharm S.A. announced that they will report Q1, 2024 results at 5:20 PM, GTB Standard Time on May 23, 2024
New Risk • Apr 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €50.9m (up 11% from FY 2022). Net income: €2.00m (up 139% from FY 2022). Profit margin: 3.9% (up from 1.8% in FY 2022). The increase in margin was driven by higher revenue.
お知らせ • Mar 01Lavipharm S.A. to Report Fiscal Year 2023 Results on Mar 21, 2024Lavipharm S.A. announced that they will report fiscal year 2023 results on Mar 21, 2024
New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin).
New Risk • Nov 10New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.5% Last year net profit margin: 2.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Minor Risk Profit margins are more than 30% lower than last year (0.5% net profit margin).
お知らせ • Nov 01Lavipharm S.A. to Report Nine Months, 2023 Results on Nov 08, 2023Lavipharm S.A. announced that they will report nine months, 2023 results on Nov 08, 2023
Board Change • Oct 19Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Board Member Vicky Kefalas was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 24Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €15.6m (up 52% from 2Q 2022). Net income: €1.63m (up 63% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022).
Board Change • Sep 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Board Member Vicky Kefalas was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 01Lavipharm S.A. to Report First Half, 2024 Results on Sep 21, 2023Lavipharm S.A. announced that they will report first half, 2024 results on Sep 21, 2023
Board Change • May 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Mar 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 17First half 2022 earnings released: EPS: €0.037 (vs €0.15 in 1H 2021)First half 2022 results: EPS: €0.037 (down from €0.15 in 1H 2021). Revenue: €21.2m (up 8.4% from 1H 2021). Net income: €1.90m (down 27% from 1H 2021). Profit margin: 9.0% (down from 13% in 1H 2021). The decrease in margin was driven by higher expenses.
Board Change • Aug 31Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.